Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis.
CD133
Cholangiocarcinoma
DUSP4
Hepatocellular carcinoma
MAPK pathway
NRAS
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
10
04
2023
accepted:
27
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
Upregulation of the mitogen-activated protein kinase (MAPK) cascade is common in hepatocellular carcinoma (HCC). Neuroblastoma RAS viral oncogene homolog (NRAS) is mutated in a small percentage of HCC and is hitherto considered insufficient for hepatocarcinogenesis. We aimed to characterize the process of N-Ras-dependent carcinogenesis in the liver and to identify potential therapeutic vulnerabilities. NRAS V12 plasmid was delivered into the mouse liver via hydrodynamic tail vein injection (HTVI). The resulting tumours, preneoplastic lesions, and normal tissue were characterized by NanoString® gene expression analysis, Western Blot, and Immunohistochemistry (IHC). The results were further confirmed by in vitro analyses of HCC cell lines. HTVI with NRAS V12 plasmid resulted in the gradual formation of preneoplastic and neoplastic lesions in the liver three months post-injection. These lesions mostly showed characteristics of HCC, with some exceptions of spindle cell/ cholangiocellular differentiation. Progressive upregulation of the RAS/RAF/MEK/ERK signalling was detectable in the lesions by Western Blot and IHC. NanoString® gene expression analysis of preneoplastic and tumorous tissue revealed a gradual overexpression of the cancer stem cell marker CD133 and Dual Specificity Phosphatases 4 and 6 (DUSP4/6). In vitro, transfection of HCC cell lines with NRAS V12 plasmid resulted in a coherent upregulation of DUSP4 and DUSP6. Paradoxically, this upregulation in PLC/PRF/5 cells was accompanied by a downregulation of phosphorylated extracellular-signal-regulated kinase (pERK), suggesting an overshooting compensation. Silencing of DUSP4 and DUSP6 increased proliferation in HCC cell lines. Contrary to prior assumptions, the G12V NRAS mutant form is sufficient to elicit hepatocarcinogenesis in the mouse. Furthermore, the upregulation of the MAPK cascade was paralleled by the overexpression of DUSP4, DUSP6, and CD133 in vivo and in vitro. Therefore, DUSP4 and DUSP6 might fine-tune the excessive MAPK activation, a mechanism that can potentially be harnessed therapeutically.
Sections du résumé
BACKGROUND
BACKGROUND
Upregulation of the mitogen-activated protein kinase (MAPK) cascade is common in hepatocellular carcinoma (HCC). Neuroblastoma RAS viral oncogene homolog (NRAS) is mutated in a small percentage of HCC and is hitherto considered insufficient for hepatocarcinogenesis. We aimed to characterize the process of N-Ras-dependent carcinogenesis in the liver and to identify potential therapeutic vulnerabilities.
METHODS
METHODS
NRAS V12 plasmid was delivered into the mouse liver via hydrodynamic tail vein injection (HTVI). The resulting tumours, preneoplastic lesions, and normal tissue were characterized by NanoString® gene expression analysis, Western Blot, and Immunohistochemistry (IHC). The results were further confirmed by in vitro analyses of HCC cell lines.
RESULTS
RESULTS
HTVI with NRAS V12 plasmid resulted in the gradual formation of preneoplastic and neoplastic lesions in the liver three months post-injection. These lesions mostly showed characteristics of HCC, with some exceptions of spindle cell/ cholangiocellular differentiation. Progressive upregulation of the RAS/RAF/MEK/ERK signalling was detectable in the lesions by Western Blot and IHC. NanoString® gene expression analysis of preneoplastic and tumorous tissue revealed a gradual overexpression of the cancer stem cell marker CD133 and Dual Specificity Phosphatases 4 and 6 (DUSP4/6). In vitro, transfection of HCC cell lines with NRAS V12 plasmid resulted in a coherent upregulation of DUSP4 and DUSP6. Paradoxically, this upregulation in PLC/PRF/5 cells was accompanied by a downregulation of phosphorylated extracellular-signal-regulated kinase (pERK), suggesting an overshooting compensation. Silencing of DUSP4 and DUSP6 increased proliferation in HCC cell lines.
CONCLUSIONS
CONCLUSIONS
Contrary to prior assumptions, the G12V NRAS mutant form is sufficient to elicit hepatocarcinogenesis in the mouse. Furthermore, the upregulation of the MAPK cascade was paralleled by the overexpression of DUSP4, DUSP6, and CD133 in vivo and in vitro. Therefore, DUSP4 and DUSP6 might fine-tune the excessive MAPK activation, a mechanism that can potentially be harnessed therapeutically.
Identifiants
pubmed: 37946160
doi: 10.1186/s12885-023-11577-9
pii: 10.1186/s12885-023-11577-9
pmc: PMC10636894
doi:
Substances chimiques
Dual-Specificity Phosphatases
EC 3.1.3.48
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
MKP2 protein, mouse
EC 3.1.3.48
Dusp6 protein, rat
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086Informations de copyright
© 2023. The Author(s).
Références
Oncogene. 2003 Mar 27;22(12):1866-71
pubmed: 12660822
Liver Int. 2018 Nov;38(11):2006-2017
pubmed: 29655291
Nature. 2011 Nov 09;479(7374):547-51
pubmed: 22080947
Eur J Surg Oncol. 2011 Jun;37(6):513-20
pubmed: 21324414
Cell Death Dis. 2019 Dec 5;10(12):928
pubmed: 31804463
Cancer Res. 2016 May 1;76(9):2612-25
pubmed: 26941286
Nat Genet. 2021 Dec;53(12):1664-1672
pubmed: 34857952
Cancer Biol Med. 2017 Aug;14(3):254-270
pubmed: 28884042
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Liver Int. 2016 Aug;36(8):1176-86
pubmed: 26716908
Am J Pathol. 2021 Sep;191(9):1651-1667
pubmed: 34129844
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
J Hepatol. 2011 Feb;54(2):311-9
pubmed: 21067840
Oncogene. 2017 Sep 7;36(36):5087-5097
pubmed: 28481866
Gastroenterology. 2019 Jul;157(1):54-64
pubmed: 30986389
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Oncol Lett. 2016 Nov;12(5):3045-3050
pubmed: 27899961
J Clin Invest. 2012 Aug;122(8):2911-5
pubmed: 22797301
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Mol Cell Biol. 1997 Sep;17(9):5598-611
pubmed: 9271435
Mol Oncol. 2022 Mar;16(5):1091-1118
pubmed: 34748271
Cell Rep Med. 2020 Nov 17;1(8):100131
pubmed: 33294856
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3844-8
pubmed: 8170999
FEBS J. 2013 Jan;280(2):489-504
pubmed: 22812510
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Life Sci Alliance. 2022 May 17;5(9):
pubmed: 35580987
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2010 May 1;126(9):2067-78
pubmed: 19711346
Mol Cancer Res. 2009 Dec;7(12):1937-45
pubmed: 19934271
Hepatology. 2015 Oct;62(4):1160-73
pubmed: 26154152
J Natl Cancer Inst. 1973 May;50(5):1195-213
pubmed: 4351393
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722184
Cell Rep. 2012 Oct 25;2(4):951-63
pubmed: 23084749
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17059-64
pubmed: 16286660
FEBS Lett. 2000 Oct 6;482(3):169-74
pubmed: 11024454
Hepatology. 2012 Mar;55(3):833-45
pubmed: 21993994
Cancers (Basel). 2021 Jun 17;13(12):
pubmed: 34204242
J Surg Oncol. 2012 Mar;105(3):273-6
pubmed: 21932411
Int J Cancer. 2013 Apr 1;132(7):1537-46
pubmed: 22965873
Curr Opin Cell Biol. 2000 Apr;12(2):186-92
pubmed: 10712927
Anticancer Res. 2011 Nov;31(11):3883-90
pubmed: 22110214
Cancer Cell. 2007 May;11(5):447-60
pubmed: 17482134
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):124-143
pubmed: 30401534
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Cell Mol Life Sci. 2016 Dec;73(23):4397-4413
pubmed: 27342992
FASEB J. 2019 Mar;33(3):4248-4260
pubmed: 30521383
Genes Dev. 1998 Oct 1;12(19):2997-3007
pubmed: 9765202
Cancer Sci. 2018 Jan;109(1):250-258
pubmed: 29150975
Front Cell Dev Biol. 2020 Feb 07;8:55
pubmed: 32117981
PLoS One. 2013;8(3):e59869
pubmed: 23555816
Cell Death Dis. 2016 Jun 23;7(6):e2269
pubmed: 27336713
Elife. 2023 Oct 17;12:
pubmed: 37846866
J Pers Med. 2022 Aug 01;12(8):
pubmed: 36013219